.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
US Department of Justice
Citi
Mallinckrodt
Baxter
Cantor Fitzgerald
UBS
Chinese Patent Office
QuintilesIMS

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
Abstract:Methods are described for the identification and preparation of nucleic acid ligand ligands to vascular endothelial growth factor (VEGF). Included in the invention are specific RNA ligands to VEGF identified by the SELEX method.
Inventor(s): Gold; Larry (Boulder, CO), Janjic; Nebojsa (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:May 18, 2001
Application Number:09/860,474
Claims:1. A method of inhibiting binding of vascular endothelial growth factor (VEGF) to its receptor, comprising: a) providing a nucleic acid ligand to VEGF; and b) contacting the nucleic acid ligand with said VEGF under conditions where a VEGF:nucleic acid binding pair is formed, whereby binding of VEGF to its receptor is inhibited.

2. The method of claim 1, wherein the nucleic acid ligand to VEGF is identified according to a method comprising the steps of: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture with VEGF, wherein nucleic acids having an increased affinity to VEGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby a VEGF nucleic acid ligand may be identified.

3. The method of claim 1, wherein said VEGF nucleic acid ligand is a ribonucleic acid.

4. The method of claim 1, wherein said VEGF nucleic acid ligand is a deoxyribonucleic acid.

5. The method of claim 1, wherein said VEGF nucleic acid ligand comprises modified nucleotides.

6. The method of claim 5, wherein said VEGF ligand is comprised of 2'-amino (2'-NH.sub.2) modified nucleotides and 2'-O-methyl (2'-OMe) modified nucleotides.

7. The method of claim 1, wherein said VEGF nucleic acid ligand is modified with a moiety that decreases the activity of endonucleases or exonucleases on the nucleic acid ligand relative to the unmodified nucleic acid ligand, without adversely affecting the binding affinity of said nucleic acid ligand.

8. The method of claim 7, wherein said moiety comprises a phosphorothioate nucleotide.

9. The method of claim 1, wherein said VEGF nucleic acid ligand is modified by a method comprising substituting nucleotide residues, wherein said residues may be chemically modified, and wherein the modification decreases the activity of endonucleases or exonucleases relative to the unmodified nucleic acid ligand, without adversely affecting the binding affinity of said nucleic acid ligand.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Moodys
Mallinckrodt
Citi
Johnson and Johnson
US Army
Farmers Insurance
McKinsey
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot